News
KRRO
7.02
+3.08%
0.21
Weekly Report: what happened at KRRO last week (1124-1128)?
Weekly Report · 6d ago
Weekly Report: what happened at KRRO last week (1117-1121)?
Weekly Report · 11/24 09:37
Weekly Report: what happened at KRRO last week (1110-1114)?
Weekly Report · 11/17 09:37
Korro Bio Cut to Hold From Buy by Jones Trading
Dow Jones · 11/14 12:26
Jones Trading Downgrades Korro Bio to Hold
Benzinga · 11/14 12:16
Korro Bio’s Strategic Shift Amidst Clinical Setbacks and Financial Stability Justifies Hold Rating
TipRanks · 11/14 10:07
RBC Capital downgrades Korro Bio (KRRO) to a Hold
TipRanks · 11/14 06:55
JonesResearch downgrades Korro Bio on KRRO-110 failure
TipRanks · 11/13 21:31
Korro Bio downgraded to Hold from Buy at JonesResearch
TipRanks · 11/13 21:26
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 11/13 21:06
Korro Bio Cut to Market Perform From Outperform by William Blair
Dow Jones · 11/13 20:58
William Blair Downgrades Korro Bio to Market Perform
Benzinga · 11/13 20:48
Korro Bio Early Trial Results Fall Short; Stock Hits New Low
Benzinga · 11/13 19:26
Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
TipRanks · 11/13 17:34
Korro Bio Cut to Sector Perform From Outperform by RBC Capital
Dow Jones · 11/13 17:31
Korro Bio Price Target Cut to $8.00/Share From $85.00 by RBC Capital
Dow Jones · 11/13 17:31
Korro Bio GAAP EPS of -$1.92, revenue of $1M
Seeking Alpha · 11/13 17:25
RBC Capital Downgrades Korro Bio to Sector Perform, Lowers Price Target to $8
Benzinga · 11/13 17:20
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 11/13 17:06
Dow Dips Over 400 Points; JD.com Posts Upbeat Q3 Results
Benzinga · 11/13 17:03
More
Webull provides a variety of real-time KRRO stock news. You can receive the latest news about Korro Bio, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About KRRO
Korro Bio, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.